挑战滤泡性淋巴瘤不可治愈教条的框架
综述提出滤泡性淋巴瘤(FL)传统上被认为不可治愈,但利妥昔单抗时代中位总生存接近20年,仅35-40%患者需超过一线治疗。借鉴慢性病毒感染及其他血液肿瘤框架,文章提出基于治疗停止后持久缓解、敏感生物标志物持续深度缓解及生存正常化等观察定义功能性治愈。早期里程碑如EFS24和CR30有助于识别长期预后良好患者。
要点
- 利妥昔单抗时代FL中位总生存接近20年,仅35-40%患者需多线治疗
- 功能性治愈可基于停药后持久缓解、MRD/PET/CT深度缓解及生存正常化定义
- EFS24和CR30等早期里程碑有助于识别长期预后良好患者
核心结论
- 长期数据挑战FL不可治愈的传统观念,支持功能性治愈概念框架。
研究设计与样本
- 综述,借鉴慢性病毒感染及慢性髓性白血病、多发性骨髓瘤等框架。
主要发现
- 利妥昔单抗治疗下FL中位总生存接近20年。
- 仅35-40%的FL患者需要超过一线治疗。
- 停药后持久缓解、MRD/PET/CT持续深度缓解及生存正常化支持功能性治愈可能。
- EFS24和CR30等早期里程碑可辅助识别长期预后良好患者。
关键数值与推荐
- 功能性治愈候选标准包括治疗停止后持久缓解。
- 功能性治愈候选标准包括无临床意义进展及敏感生物标志物(MRD、PET/CT)持续深度缓解。
- 功能性治愈候选标准包括相对一般人群的生存正常化及患者报告生活质量。
- EFS24指24个月无事件生存,CR30指30个月完全缓解。
临床怎么用
- 重新审视FL自然史假设,治疗目标可考虑功能性治愈。
- 利用EFS24和CR30等早期里程碑识别长期预后良好患者。
- 关注停药后持久缓解及MRD/PET/CT深度缓解以指导随访策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Follicular lymphoma (FL) has traditionally been considered an incurable malignancy characterized by repeated relapses. However, emerging long-term data are increasingly challenging this paradigm. With rituximab, median overall survival approaches 20 years, and only 35-40% of patients require more than one treatment line. Drawing on frameworks established in chronic viral infections and other hematologic malignancies, including chronic myeloid leukemia and multiple myeloma, this review examines the evolving concepts of cure and functional cure. We propose a framework supporting the probability of functional cure based on several observations: durable remission following treatment discontinuation; absence of clinically meaningful progression, sustained deep remission defined by sensitive biomarkers including minimal residual disease and PET/CT; and normalization of survival relative to the general population and patient-reported quality of life. We further discuss how early clinical milestones, such as event-free survival at 24 months (EFS24) and complete remission at 30 months (CR30), may also assist in identifying patients with particularly favorable long-term disease trajectories. Together, these findings support reconsideration of long-standing assumptions regarding the natural history of FL and provide a conceptual framework for defining functional cure in FL, with implications for therapeutic goals, survivor follow-up strategies, biomarker development, and personalized therapeutic.
引用
- Magnano L, López-Guillermo A, Maurer MJ, et al. A framework to challenge the dogma of incurability in follicular lymphoma. Blood. 2026. PMID: 42684986. doi:10.1182/blood.2026035096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。